BACKGROUNDPatients with autoimmune diseases, for the most part, need continuous or prolonged use of immunosuppressive drugs. In the midst of the therapeutic arsenal, the use of the subcutaneous (SC) route has been an important treatment option for such patients. The objective of this study was to evaluate the perception of patients regarding the use of immunosuppressive drugs administered via the SC route. METHODSAn observational, cross-sectional study was carried out with the application of a questionnaire to patients over 18 years of age, followed up at the rheumatology center in a tertiary hospital, users of at least two doses of immunosuppressive medication administered subcutaneously. RESULTSA total of 123 patients were interviewed, most of them with rheumatoid arthritis (76%) and spondyloarthropathy (19%), of female gender (84%), with a mean age of 66 years. Medication at home was taken for 76% of the patients, and in 68% of the cases the application was done by the patient, with 27% reporting some difficulty at the time of application and 30% preferring to modify it to perform it in a supervised way. However, only 14% of them reported some degree of insecurity in performing it at home; 24% of the patients apply the medication in some health establishment, being 50% in the basic health units and 50% in the infusion center of the hospital; 85% of respondents stored the medication correctly, but 12% reported recurrent lack of light in their home. Of the patients who took their medication at home, 18% reported delays in taking the medication versus 13% of the group who attended a health facility. CONCLUSIONThe use of SC immunosuppressive drugs has been used for a long time in autoimmune diseases and an adequate explanation about the care with the medication, as well as its application, in addition to the patients' understanding of their own condition, are factors that favor adherence to the medication. treatment and, therefore, better outcomes.
BACKGROUNDSystemic lupus erythematosus (SLE) is a chronic autoimmune disorder, characterized by alternating disease activity and remission, often affecting young women, in a 9:1 ratio. Cutaneous lupus affects the skin and mucosa, and lesions in the oral cavity are varied, such as canker sores and ulcers. SLE is associated with a higher risk of developing neoplastic transformation, whose mechanism is still poorly recognized; however, it is suggested that disease activity and prolonged use of immunosuppressive therapy are important triggers. There are few cases of squamous cell carcinoma (SCC) reported in the literature, especially in the oral cavity. The report describes a case of SCC in the tongue diagnosed in a patient with SLE. CASE REPORTA 26-year-old female patient undergoing regular follow-up at a tertiary hospital rheumatology outpatient clinic, diagnosed with SLE in 2011, associated with antiphospholipid syndrome (APS). She was diagnosed with human papillomavirus (HPV) infection in 2020 after colposcopy, which showed lowgrade squamous intraepithelial neoplasm. At the time, she received treatment with laser therapy and maintained remission, with routine consultations with gynecology. In 2021, she developed an ulcerated lesion on the right lateral surface of the tongue, whose pathology study showed a well-differentiated, invasive, keratinizing SCC. She underwent right hemiglossectomy, with lymphatic dissection of the homolateral cervical chain, protective tracheostomy and tongue graft, followed by 30 sessions of radiotherapy. The graft was lost, however, therapeutic success was achieved, evidenced by free margins in the anatopathological sample and the absence of distant metastasis. CONCLUSIONSLE is a potentially malignant condition and there are few reports in the literature of association with oral SCC. Oral ulcerated lesions are common in SLE; however, it is important to consider malignant transformations, as in the case above. The attending physician must be aware of this possibility, taking into account clinical suspicion and early identification of cases, in order to obtain better outcomes.
BACKGROUNDSecukinumab (SEC) is a human monoclonal antibody that inhibits IL-17A. It is effective in controlling signs/symptoms of psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (SpA), in refractory patients, in those who had adverse effects to immunobiologicals and also in those naïve to immunobiological drugs. The aim of this study is to evaluate clinical and epidemiological characteristics of patients using SEC, with follow-up in psoriasis and spondyloarthritis clinics in a tertiary hospital. METHODSRetrospective medical record review study, including 37 patients who met classification criteria for PsO, PsA and SpA, and used at least five SEC injections (induction dose) between 01/2017 and 06/2021, in a tertiary hospital. RESULTSThirty-seven patients were divided into two groups: 23 with PsO (8) or PsA (15) (group 1) and 14 with SpA (group 2). Sixty-five percent of group 1 patients were female. The mean age was 55.3 years old and average time of diagnosis was 8.5 years; 66.7% of PsA patients had isolated arthritis, 13% enthesitis and 7% isolated dactylitis; 53% of the patients showed axial symptoms in association with peripheral harm; 4% of patients had history of uveitis and 9% inflammatory bowel disease (IBD). Secukinumab was indicated by active disease in 74% of the patients and suspended for secondary failure in 9% of the cases. Average treatment time was 22 months (standard deviation, SD = 13.71). Of group 2, 57% of patients were male. The mean age was 46.9 years old and average time of diagnosis was 12.1 years; 14% of the cases had arthritis, 14% enthesitis and 14% arthritis plus enthesitis, beyond axial disease; 36% of the patients had uveitis and 7% IBD in their medical records. Secukinumab was indicated by active disease in 86% of the patients and suspended for secondary failure in 14% of the cases. Average treatment time was 24 months (SD = 11.32). One patient had fungal vulvovaginitis, without the need to interrupt medication. There were not flares or reactivation of uveitis or IBD. There was statistically significant difference regarding the initial presence of uveitis in group 2 (36% vs. 4%, p = 0.02) and older ages in group 1 (55.3 vs. 46.9, p = 0.039). CONCLUSIONIn the studied patients, similar characteristics were observed regarding demographic data, indication, time of use and discontinuation rates of SEC. In this real-life study, the medication was shown to be safe and effective, as well as in large clinical trials.
BACKGROUNDPeriodontitis and rheumatoid arthritis (RA) may be linked to each other. In both diseases, hard and soft tissue destruction is seen with pro inflammatory cytokines such as IL (interleukin)-6, TNF-alpha and IL-1 playing a role. Several studies have detected increased periodontal disease in RA patients and periodontitis is considered to influence in the RA appearance and in the disease activity. The aim of this work was to study the oral health of RA patients comparing it with controls in a Brazilian sample from a public health rheumatologic center. METHODSOne hundred and sixteen RA patients and 68 controls (patients' companions) were compared for epidemiological data and presence of periodontal disease evaluated by number of remaining teeth, presence of bacterial plaque, bleeding on probing, probing depth and clinical level of gingival insertion. Periodontitis was classified in severe, moderate and mild. Data on comorbidities was also collected RESULTSPatients and controls were paired for gender, age, tobacco use, years of formal education and presence of diabetes mellitus, hypothyroidism, hypertension and dyslipidemia. Rheumatoid arthritis patients and controls have the same amount of teeth loss/ person (11 vs. 9; p = 0.84); RA patients had more calculus (p = 0.02); dental plaques (p = 0.04); gingival retraction (p = 0.02) and bleeding (p = 0.01). Although the number of individuals with periodontitis was higher in RA patients (56.1% vs. 32.8%), the severity of periodontitis was similar in both groups (p = ns). Diabetes and hypothyroidism also associated with periodontitis (p = 0.01 and 0.02, respectively). In a model of logistic regression built to assess the independence of association of RA and its comorbidities with periodontitis, only diabetes (p = 0.006; OR = 5.2; 95%CI = 1.5-17.1) and RA (p = 0.01; OR = 2.45; 95%CI = 1.1-5.2) remained independent. CONCLUSIONThis case control study shows that oral health in RA patients is poorer than controls. Diabetes mellitus also associated with periodontitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.